Why Sierra Oncology Stock Is Soaring Today
Shares of rare-cancer company Sierra Oncology (NASDAQ: SRRA) jumped by as much as 38% in premarket trading Wednesday morning. The drugmaker's stock is surging this morning in response to a $1.9 billion buyout agreement with U.K. pharma giant GlaxoSmithKline (NYSE: GSK).
Sierra's shareholders will reportedly receive $55 per share in cash, which represents a 39% premium relative to where Sierra's shares closed Tuesday afternoon. The transaction is expected to close in the third quarter of 2022.
Image source: Getty Images.
Source Fool.com
